-- ABG Sundal Collier on Monday initiated its coverage of biopharmaceutical company Camurus (CAMX.ST) with a buy rating and a price target of 750 kronor.
(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)